
    
      The primary objective is to evaluate the efficacy of IGIV-C in subjects with generalized
      myasthenia gravis (MG) on standard of care treatment at study entry in terms of improvement
      in MG symptoms as measured by the mean change in Quantitative Myasthenia Gravis (QMG) score
      from Baseline (Week 0) to Week 24 as compared to placebo.

      The safety objective of this study is to evaluate the safety and tolerability of IGIV-C
      loading dose of 2 g/kg followed by 7 maintenance dosages of 1 g/kg every 3 weeks through Week
      21 in subjects with MG.
    
  